Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stent worries may help Plavix

Executive Summary

FDA's Circulatory System Devices Panel recommends extended use of Sanofi-Aventis/Bristol-Myers Squibb's Plavix (clopidogrel) for reducing risk of thrombosis associated with drug-eluting stents. During its Dec. 7-8 meeting, the panel suggested FDA align DES labeling with American Heart Association guidelines that the antiplatelet therapy be taken for up to a year if a patient does not exhibit excessive bleeding. An observational study published in the Dec. 5 Journal of the American Medical Association found better outcomes were achieved the longer patients took Plavix, up to one year. FDA is considering changing DES labeling to reflect the need for anticlotting regimens that last longer than the three months recommended for Johnson & Johnson/Cordis' Cypher sirolimus-eluting stent and the six months recommended for Boston Scientific's Taxus paclitaxel-eluting stent...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

PS047857

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel